BioCryst Pharmaceuticals Inc
$ 9.50
-0.21%
17 Apr - close price
- Market Cap 2,387,622,000 USD
- Current Price $ 9.50
- High / Low $ 9.67 / 9.43
- Stock P/E 7.87
- Book Value -0.56
- EPS 1.21
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.43 %
- ROE -19.25 %
- 52 Week High 11.31
- 52 Week Low 6.00
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
Analyst Target Price
$21.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-03 | 2025-08-05 | 2025-05-05 | 2025-02-24 | 2024-11-04 | 2024-08-05 | 2024-05-06 | 2024-02-26 | 2023-11-02 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 1.1212 | 0.16 | 0.02 | 0.0001 | -0.13 | -0.07 | -0.06 | -0.17 | -0.28 | -0.19 | -0.24 | -0.28 |
| Estimated EPS | 0.0344 | 0.05 | 0.01 | -0.21 | -0.0604 | -0.06 | -0.17 | -0.21 | -0.24 | -0.23 | -0.23 | -0.3 |
| Surprise | 1.0868 | 0.11 | 0.01 | 0.2101 | -0.0696 | -0.01 | 0.11 | 0.04 | -0.04 | 0.04 | -0.01 | 0.02 |
| Surprise Percentage | 3159.3023% | 220% | 100% | 100.0476% | -115.2318% | -16.6667% | 64.7059% | 19.0476% | -16.6667% | 17.3913% | -4.3478% | 6.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCRX
2026-04-16 10:10:30
BioCryst Pharmaceuticals (BCRX) recently appointed Sandeep M. Menon as chief R&D officer, a move that could significantly influence its pipeline, given his expertise in rare diseases and AI-driven development. While this strengthens R&D leadership, the company's investment narrative remains heavily reliant on the success of ORLADEYO. Though an oral pellet formulation of ORLADEYO for children was approved, the long-term investment case will depend on BioCryst's ability to diversify beyond this single drug and develop credible follow-on therapies.
2026-04-16 10:09:53
Phocas Financial Corp. recently acquired a new stake of 250,797 shares in BioCryst Pharmaceuticals (NASDAQ:BCRX), valued at approximately $1.96 million. This investment represents about 0.12% of the company. BioCryst Pharmaceuticals exceeded Q4 earnings expectations with $1.12 EPS against a $0.07 consensus and revenue of $163.28 million, a 209% increase year-over-year.
2026-04-16 00:09:53
Wall Street analysts are optimistic about BioCryst Pharmaceuticals Inc (BCRX.O) stock, with a forecast for its price to rise, based on 9 "Buy" and 2 "Hold" ratings. RBC Capital and Wedbush both recently increased their price targets for BCRX, maintaining "Outperform" ratings due to strong Q1 expectations, robust M&A, and positive company guidance following the Astria Therapeutics acquisition.
2026-04-15 13:39:24
BioCryst Pharmaceuticals recently appointed Sandeep M. Menon, an expert in rare disease and AI-driven R&D, as its Chief Research and Development Officer. This move is expected to influence the company’s pipeline prioritization but does not immediately alter its reliance on the HAE drug ORLADEYO, which recently received FDA approval for a new oral pellet formulation for children. Investors will be watching how Menon's leadership balances extending ORLADEYO's lifecycle with developing new credible therapies, as the company's financial forecasts project significant revenue and earnings growth by 2029.
2026-04-15 11:09:00
BioCryst Pharmaceuticals, Inc. announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases.
2026-04-15 10:39:56
BioCryst Pharmaceuticals, Inc. announced it will report its first quarter 2026 financial results on Wednesday, May 6, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
